Group 1 - A-shares indices opened lower but closed higher, with the Shanghai Composite Index reaching a ten-year high, driven by strong performance in the consumer sector [1] - The China Securities Food and Beverage Index rose by 0.69%, marking six consecutive days of gains, with notable stocks including San Yuan and Xin Nuo Wei [1] - The China A500 Index increased by 1.43%, with multiple stocks such as Tianhua New Energy and Xinjie Materials rising over 10% [1] Group 2 - During the "Double 11" shopping festival from October 21 to November 11, the national postal and express delivery companies processed 13.938 billion packages, achieving significant year-on-year growth [2] - Instant retail emerged as the biggest surprise during the "Double 11" festival, with Meituan's flash purchase platform reporting record highs in transaction volume, user numbers, and per capita spending [2] - Zhongyin Securities anticipates a recovery in the food and beverage sector, highlighting resilient performance in the liquor sector and the recovery of mass consumer goods [2] - Shengan Securities noted that subcategories within mass consumer goods, such as snacks and yellow wine, continue to show growth, with Q3 revenue for leading companies in these categories maintaining good year-on-year growth [2]

今日具体限售解禁股情况如下： 智通财经APP获悉，11月14日共有3家上市公司的限售股解禁，解禁总市值约48.85亿元。 | 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 京城股份 | 600860 | 股权激励限售流通 | 183.6万 | | 棒杰股份 | 002634 | 股权激励限售流通 | 137.25万 | | 新诺威 | 300765 | 增发A股原股东配售上市 | 1.31亿 | ...

证券日报网讯11月13日晚间，新诺威（300765）发布关于发行股份购买资产并募集配套资金暨关联交易 之部分限售股份解除限售上市流通的提示性公告称，公司本次解除限售股东数量共计1名，解除限售股 份数量为157，520，510股，占公司总股本的11.2147%。本次限售股份可上市流通日期为2025年11月17 日(星期一)。 ...

格隆汇11月13日｜新诺威公告称，本次解除限售股东为恩必普药业，数量1名，解除限售股份1.58亿 股，占公司总股本的11.2147%，可上市流通日为2025年11月17日。业绩承诺方面，2022 - 2024年石药圣 雪已完成业绩承诺，无需进行业绩补偿；截至2024年底，其100%股权未发生减值，无需减值补偿。独 立财务顾问认为，本次限售股份解除限售和上市流通符合规定，相关股东无违反承诺情况。 ...

新诺威公告称，本次解除限售股东为恩必普药业，数量1名，解除限售股份1.58亿股，占公司总股本的 11.2147%，可上市流通日为2025年11月17日。业绩承诺方面，2022 - 2024年石药圣雪已完成业绩承诺， 无需进行业绩补偿；截至2024年底，其100%股权未发生减值，无需减值补偿。独立财务顾问认为，本 次限售股份解除限售和上市流通符合规定，相关股东无违反承诺情况。 ...

证券代码：300765 证券简称：新诺威 公告编号：2025-087 石药创新制药股份有限公司 关于发行股份购买资产并募集配套资金暨关联交易之部分 限售股份解除限售上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： （二）上述股份发行完成后至本公告披露之日公司总股本变化情况 公司本次发行股份购买资产并募集配套资金暨关联交易之向特定对象发行 股份募集配套资金的新增股份 31,486,146 股于 2023 年 3 月 10 日在深圳证券交易 所创业板上市，本次发行后公司总股本增加至 650,412,308 股。 公司于 2023 年 4 月 27 日完成 2022 年年度权益分派，其中以资本公积金向 全体股东每 10 股转增 8 股，转增后公司总股本增加至 1,170,742,154 股。 公司于 2024 年 4 月 25 日完成 2023 年年度权益分派，其中以资本公积金向 全体股东每 10 股转增 2 股，转增后公司总股本增加至 1,404,592,944 股。 2、本次限售股份可上市流通日为 2025 年 11 月 17 日 ...

之 部分限售股份解除限售上市流通 国投证券股份有限公司 关于 石药创新制药股份有限公司 发行股份购买资产并募集配套资金 暨关联交易 的核查意见 独立财务顾问 二零二五年十一月 国投证券股份有限公司（以下简称"国投证券"、"独立财务顾问"）作为 石药创新制药股份有限公司（以下简称"石药创新"、"公司"）发行股份购买 资产并募集配套资金暨关联交易（以下简称"本次交易"）的独立财务顾问，根 据《上市公司重大资产重组管理办法》《上市公司并购重组财务顾问业务管理办 法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等相关规定，对本次交易部分限 售股份解除限售情况进行了核查，具体核查情况如下： 一、本次解除限售的股份取得和股本变化情况 （一）本次解除限售的股份取得情况 2022 年 10 月 12 日，公司收到中国证券监督管理委员会（以下简称"中国 证监会"）于 2022 年 10 月 8 日出具的《关于同意石药集团新诺威制药股份有限 公司向石药集团恩必普药业有限公司发行股份购买资产并募集配套资金注册的 批复》（证监许可[2022]2365 号），中国证监 ...

Group 1 - The core viewpoint of the news is that XinNuoWei's stock price increased by 5.18%, reaching 33.27 CNY per share, with a trading volume of 260 million CNY and a turnover rate of 0.64%, resulting in a total market capitalization of 46.731 billion CNY [1] - XinNuoWei, established on April 5, 2006, and listed on March 22, 2019, is primarily engaged in the research, production, and sales of functional foods, with revenue composition being 88.93% from functional foods and raw materials, 8.91% from biopharmaceuticals, and 2.16% from other sources [1] Group 2 - From the perspective of major circulating shareholders, E Fund's Chuangye ETF (159915) reduced its holdings by 1.3253 million shares in the third quarter, now holding 7.868 million shares, which accounts for 0.63% of circulating shares, with an estimated floating profit of approximately 12.9035 million CNY [2] - E Fund's Chuangye ETF (159915) was established on September 20, 2011, with a current scale of 110.2 billion CNY, achieving a year-to-date return of 47.69% and a one-year return of 32.24%, ranking 574 out of 4216 and 858 out of 3951 in its category, respectively [2] Group 3 - The fund managers of E Fund's Chuangye ETF are Cheng Xi and Liu Shurong, with Cheng having a tenure of 9 years and 193 days and a total fund asset size of 250.121 billion CNY, achieving a best return of 131.04% and a worst return of -67.89% during his tenure [3] - Liu Shurong has a tenure of 8 years and 121 days, managing assets totaling 141.127 billion CNY, with a best return of 194.12% and a worst return of -48.01% during his tenure [3]

Core Viewpoint - The announcement indicates that the company's subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received the acceptance notice for the marketing application of the drug Patuzumab Injection from the National Medical Products Administration [1] Group 1 - The acceptance of the marketing application is a significant step for the company in advancing its product pipeline [1] - The drug Patuzumab Injection is likely to contribute to the company's revenue growth upon successful commercialization [1]

Core Viewpoint - New Horizon announced that its subsidiary, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the marketing application of Pertuzumab injection, targeting HER2-positive breast cancer [1]. Group 1 - The marketing application for Pertuzumab injection has been accepted, indicating progress in the drug's approval process [1]. - Pertuzumab injection is a recombinant humanized anti-HER2 monoclonal antibody that specifically binds to the extracellular dimerization domain II of HER2, blocking the dimerization of HER2 with itself or other HER family members [1]. - The mechanism of action involves blocking the cell cycle and inducing apoptosis, which is crucial for treating HER2-positive breast cancer [1].